Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2023 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel...
September 26, 2023 07:30 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022) Soleno Intends to Submit a New...
September 25, 2023 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Present at the Cantor Global Healthcare Conference

REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
August 16, 2023 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
August 08, 2023 16:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
May 09, 2023 16:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
May 03, 2023 16:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Top-line data expected in Q3 2023 and has the potential to support an NDA submission for DCCR in Prader Willi Syndrome Enrollment completion satisfies closing condition on December 2022 Securities...
March 28, 2023 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days

REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
March 21, 2023 16:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

REDWOOD CITY, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
March 07, 2023 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...